Candidate biomarkers in heart failure with reduced and preserved ejection fraction

Biomarkers

Volumn 20, Issue 4, 2015, Pages 258-265

  Sinning, Christoph ^a   Zengin, Elvin ^a   Zeller, Tanja ^a,b   Schnabel, Renate B ^a,b   Blankenberg, Stefan ^a,b   Westermann, Dirk ^a,b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Growth differentiation factor 15; heart failure with reduced and preserved ejection fraction; highly sensitive determined troponin; soluble source of tumorigenicity 2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; FRACTALKINE; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 33; PROADRENOMEDULLIN; TROPONIN; UNTRANSLATED RNA; ADRENOMEDULLIN; GDF15 PROTEIN, HUMAN; MID-REGIONAL PRO-ADRENOMEDULLIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ARTICLE; CARDIOVASCULAR RISK; CARDITIS; EXTRACELLULAR MATRIX; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED AND PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; SECONDARY PREVENTION; HEART FAILURE; HEART STROKE VOLUME; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADRENOMEDULLIN; BIOMARKERS; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; STROKE VOLUME;

EID: 84940023364     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1068856     Document Type: Article

References (73)

1. Altin SE, Schulze PC. (2011). Fractalkine: a novel cardiac chemokine? Cardiovasc Res 92: 361-2
2. Anand IS, Kempf T, Rector TS, et al. (2010). Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122: 1387-95
3. Anand IS, Rector TS, Cleland JG, et al. (2011). Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4: 569-77
4. Anand IS, Rector TS, Kuskowski M, et al. (2013). Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 15: 511-18
5. Baessler A, Strack C, Rousseva E, et al. (2012). Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 14: 1240-8
6. Bayes-Genis A, De Antonio M, Vila J, et al. (2014). Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63: 158-66
7. Blankenberg S, Zeller T, Saarela O, et al. (2010). Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121: 2388-97
8. Braga JR, Tu JV, Austin PC, et al. (2013). Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail 6: 193-202
9. Brouwers FP, De Boer RA, van der Harst P, et al. (2013). Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34: 1424-31
10. Brouwers FP, Hillege HL, van Gilst WH, van Veldhuisen DJ. (2012). Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. Curr Heart Fail Rep 9: 363-8
11. Chen LQ, De Lemos JA, Das SR, et al. (2013). Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 59: 536-46
12. Cheng JM, Akkerhuis KM, Battes LC, et al. (2013). Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 15: 1350-62
13. Coglianese EE, Larson MG, Vasan RS, et al. (2012). Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58: 1673-81
14. Daniels LB, Clopton P, Laughlin GA, et al. (2011). Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123: 2101-10
15. De Boer RA, Edelmann F, Cohen-Solal A, et al. (2013). Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 15: 1095-101
16. De Boer RA, Lok DJ, Jaarsma T, et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43: 60-8
17. De Lemos JA, Drazner MH, Omland T, et al. (2010). Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304: 2503-12
18. deFilippi CR, De Lemos JA, Christenson RH, et al. (2010). Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304: 2494-502
19. Dieplinger B, Egger M, Koehler W, et al. (2012). Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit-the Linz Intensive Care Unit (LICU) study. Clin Chim Acta 413: 587-93
20. Escher F, Vetter R, Kuhl U, et al. (2011). Fractalkine in human inflammatory cardiomyopathy. Heart 97:733 - 9
21. Fiedler J, Batkai S, Thum T. (2014). MicroRNA-based therapy in cardiology. Herz 39: 194-200
22. Funke-Kaiser A, Havulinna AS, Zeller T, et al. (2014a). Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med 46: 155-62
23. Funke-Kaiser A, Mann K, Colquhoun D, et al. (2014b). Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. Int J Cardiol 172: 411-18
24. Gaggin HK, Januzzi JL, Jr. (2013). Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832: 2442-50
25. Gaggin HK, Szymonifka J, Bhardwaj A, et al. (2014). Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2: 65-72
26. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. (2014). Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol 172: e250-2
27. Gupta SK, Piccoli MT, Thum T. (2014). Non-coding RNAs in cardiovascular ageing. Ageing Res Rev 17C: 79-85
28. Heger J, Schiegnitz E, von Waldthausen D, et al. (2010). Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 224: 120-6
29. Heymans S, Schroen B, Vermeersch P, et al. (2005). Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112: 1136-44
30. Hlatky MA, Greenland P, Arnett DK, et al. (2009). Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119: 2408-16
31. Ho JE, Larson MG, Ghorbani A, et al. (2013). Soluble ST2 predicts elevated SBP in the community. J Hypertens 31: 1431-6
32. Ho JE, Liu C, Lyass A, et al. (2012). Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-56
33. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95: 948-54
34. Jungbauer CG, Riedlinger J, Block D, et al. (2014). Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark Med 8: 777-89
35. Kempf T, Zarbock A, Widera C, et al. (2011). GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17: 581-8
36. Kohli P, Bonaca MP, Kakkar R, et al. (2012). Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 58: 257-66
37. Koller L, Blum S, Korpak M, et al. (2014). Predictive power of the fractalkine receptor CX3CR1 on CD4 T cells in patients with chronic heart failure. Int J Cardiol 171: 96-7
38. Komajda M. (2012). Management of heart failure: a challenge for healthcare systems. Bull Acad Natl Med 196: 1159-65; discussion 1165-7
39. Komajda M, Lam CS. (2014). Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35: 1022-32
40. Kumarswamy R, Bauters C, Volkmann I, et al. (2014). The circulating long non-coding RNA LIPCAR predicts survival in heart failure patients. Circ Res 114: 1569-75
41. Kumarswamy R, Thum T. (2013). Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 113: 676-89
42. Ky B, French B, McCloskey K, et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4: 180-7
43. Liew FY, Pitman NI, McInnes IB. (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10: 103-10
44. Lin DC, Diamandis EP, Januzzi JL Jr, et al. (2014). Natriuretic peptides in heart failure. Clin Chem 60: 1040-6
45. Maisel A, Mueller C, Nowak R, et al. (2010). Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-76
46. Masson S, Anand I, Favero C, et al. (2012). Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125: 280-8
47. McMurray JJ, Adamopoulos S, Anker SD, et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-847
48. Motiwala SR, Szymonifka J, Belcher A, et al. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15: 1157-63
49. Nair N, Kumar S, Gongora E, Gupta S. (2013). Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 376: 33-40
50. Neumann JT, Tzikas S, Funke-Kaiser A, et al. (2013). Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis 228: 451-9
51. Paulus WJ, Tschope C, Sanderson JE, et al. (2007). How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28: 2539-50
52. Richter B, Koller L, Hohensinner PJ, et al. (2012). Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 108: 1220-7
53. Richter B, Koller L, Hohensinner PJ, et al. (2013). A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 168: 1251-7
54. Santhanakrishnan R, Chong JP, Ng TP, et al. (2012). Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14: 1338-47
55. Sato Y, Fujiwara H, Takatsu Y. (2012). Cardiac troponin and heart failure in the era of high-sensitivity assays. J Cardiol 60: 160-7
56. Shah RV, Truong QA, Gaggin HK, et al. (2012). Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33: 2197-205
57. Sharma UC, Pokharel S, van Brakel TJ, et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-8
58. Siemelink MA, Zeller T. (2014). Biomarkers of coronary artery disease: the promise of the transcriptome. Curr Cardiol Rep 16: 513 - 23
59. Thum T. (2014). Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 11: 655-63
60. Thygesen K, Alpert JS, Jaffe AS, et al. (2012). Third universal definition of myocardial infarction. Circulation 126: 2020-35
61. Tschope C, Kasner M, Westermann D, et al. (2005). The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26: 2277-84
62. van der Velde AR, Gullestad L, Ueland T, et al. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6: 219-26
63. van Kimmenade RR, Januzzi JL Jr. (2012). Emerging biomarkers in heart failure. Clin Chem 58: 127-38
64. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48: 1217-24
65. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. (2013). B-type natriuretic Peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61: 1498-506
66. Wang TJ, Levy D, Benjamin EJ, Vasan RS. (2003). The epidemiology of asymptomatic left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138: 907-16
67. Wang TJ, Wollert KC, Larson MG, et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126: 1596-604
68. Westermann D, Kasner M, Steendijk P, et al. (2008). Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117:2051 - 60
69. Westermann D, Lindner D, Kasner M, et al. (2011a). Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44 - 52
70. Westermann D, Savvatis K, Lindner D, et al. (2011b). Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 124:2082 - 93
71. Wild PS, Schnabel RB, Lubos E, et al. (2012). Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem 58: 226-36
72. Xuan W, Liao Y, Chen B, et al. (2011). Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 92: 385-93
73. Yancy CW, Jessup M, Bozkurt B, et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62: e147-239